Document is current
Any future updates will be listed below
-
Authors
García-García, I.
Guerra-García, P.
Ferreras, C.
Borobia, A. M.
Carcas, A. J.
Queiruga-Parada, J.
Vicario, J. L.
Mirones, I.
Solano, C.
Eguizabal, C.
Soria, B.
Pérez-Martínez, A. https://orcid.org/0000-0002-6436-9195
-
Funding
Funding for this research was provided by:
CRIS Cancer Foundation
Fundación Mutua Madrileña (AP176182020)
Conselleria de Sanitat Universal i Salut Pública (AVI-GVA COVID-19-68)
- License Information
-
More Information
Article History
Received: 31 May 2021
Accepted: 14 September 2021
First Online: 2 October 2021
Declarations
:
: This study follows the principles of the Helsinki Declaration 2013. It was designed and shall be implemented, executed, and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (Law 14/2007 of 3 July 2007 on Biomedical Research (Ley de Investigación Biomédica, BOE 159 of 4 July 2007) and the directive 2004/23/EC of the European Parliament and of the council of 31 March 2004). The entire protocol was reviewed and approved by the Ethics Committee CEIC Hospital Universitario La Paz (identifier: Clinical Ethical Approval No. HULP:5579).
: Not applicable.
: CF, BS, and AP-M filed a patent on this topic. BS received fees from Laminar Pharma, Abbvie, Celgene, Gilead, Sanofi, and Novo-Nordisk not related to this work.
